☆ 3.8 Article

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Daniel Tobias Michaeli et al.

Summary: This study evaluates the cost-effectiveness of different lipid-lowering therapies for cardiovascular prevention in Germany's healthcare system. The results suggest that the combination of icosapent ethyl with statins is cost-effective for primary prevention, while icosapent ethyl, ezetimibe, evolocumab, and alirocumab provide additional patient benefit in secondary prevention at different economic costs.

CARDIOVASCULAR DRUGS AND THERAPY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction

Zanfina Ademi et al.

Summary: The study aimed to assess the cost-effectiveness of icosapent ethyl in combination with statin therapy for the prevention of cardiovascular disease in the Australian public healthcare system. Results suggest that the combination therapy may be cost-effective, especially in the secondary preventive setting.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis

Ronen Arbel et al.

Summary: This study estimated the number of preventable major adverse cardiovascular events (MACE) when providing Icosapent ethyl (IPE) for primary versus secondary prevention, showing that prioritizing IPE therapy for patients with established cardiovascular disease may offer significantly more value for money.

AMERICAN JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Reduction in Revascularization With Icosapent Ethyl Insights From REDUCE-IT Revascularization Analyses

Benjamin E. Peterson et al.

Summary: Icosapent ethyl reduces the need for coronary revascularizations in patients with elevated triglycerides and increased cardiovascular risk who are receiving statin therapy, showing significant reduction in first and subsequent revascularizations as well as coronary artery bypass grafting.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Subodh Verma et al.

Summary: In patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl in the REDUCE-IT trial led to significant reductions in both first and recurrent ischemic events compared to placebo, with similar safety findings between groups.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Arjun Majithia et al.

Summary: In the REDUCE-IT trial, icosapent ethyl reduced fatal and nonfatal ischemic events across a broad range of baseline eGFR categories.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry

Fabien Picard et al.

Summary: Through the data from REACH registry, it was found that 11.3% of patients met the eligibility criteria for the REDUCE-IT trial. These eligible patients had a higher risk of cardiac atherothrombotic events but a lower risk of stroke compared to those ineligible for the trial due to lower triglyceride levels.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Prakriti Gaba et al.

Summary: The REDUCE-IT trial found that IPE significantly reduced cardiovascular events as reported by investigators with a high degree of concordance between investigator-reported and adjudicated endpoints.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

Henry N. Ginsberg et al.

Summary: Recent research supports a causal association between triglycerides, triglyceride-rich lipoproteins, and their remnants with cardiovascular diseases, emphasizing the importance of focusing on their impact on heart health. Targeting levels of triglycerides and their remnants may potentially reduce the risk of atherosclerotic cardiovascular diseases.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

Henry N. Ginsberg et al.

Summary: This article reviews the impact of triglycerides and triglyceride-rich lipoproteins on cardiovascular disease risk, emphasizing that reducing levels of TRL and their remnants can help reduce the risk of ASCVD.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

REDUCE-IT USA Results From the 3146 Patients Randomized in the United States

Deepak L. Bhatt et al.

CIRCULATION (2020)

添加到收藏夹

Article Health Care Sciences & Services

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease

Patricia G. Synnott et al.

Journal of Managed Care & Specialty Pharmacy (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES])

Nathan D. Wong et al.

AMERICAN JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014

Wenjun Fan et al.

CARDIOLOGY AND THERAPY (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease

Fabien Picard et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT

Deepak L. Bhatt et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey

Wenjun Fan et al.

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial

Deepak L. Bhatt et al.

CLINICAL CARDIOLOGY (2017)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

The National Prevention Strategy: Leveraging Multiple Sectors to Improve Population Health

Boris D. Lushniak et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2015)

添加到收藏夹

Article Economics

Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

Sean D. Sullivan et al.

VALUE IN HEALTH (2014)

添加到收藏夹

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.